Biogen Inc. (ETR:IDP)
Germany · Delayed Price · Currency is EUR 126.10
-3.45 (-2.66%)
Oct 10, 2025, 5:35 PM CET
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
€1,119,322
Profits / Employee
€171,364
Market Cap
18.49B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Healthineers AG | 72,000 |
| Merck KGaA | 59,020 |
| Bayer Aktiengesellschaft | 91,864 |
| Fresenius SE & Co. KGaA | 176,486 |
| Fresenius Medical Care AG | 111,513 |
| Sartorius Aktiengesellschaft | 13,528 |
| Fielmann Group AG | 24,363 |
| Carl Zeiss Meditec AG | 5,730 |
Biogen News
- 4 days ago - Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation - GuruFocus
- 4 days ago - Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug - GuruFocus
- 5 days ago - Eisai And Biogen : LEQEMBI IQLIK Injection Now Available In U.S. For Early Alzheimer's Treatment - Nasdaq
- 5 days ago - Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S. - GuruFocus
- 5 days ago - Biogen (BIIB) Launches New Alzheimer's Treatment Option in U.S. - GuruFocus
- 5 days ago - Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease - Benzinga
- 5 days ago - Eisai and Biogen Announce U.S. Availability of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease - Wallstreet:Online
- 5 days ago - Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease - PRNewsWire